EXOCORRECT

WIPO WIPO 2021

Schützen Sie diese Marke vor Nachahmern!

Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.

Die Internationale Marke EXOCORRECT wurde als Wortmarke am 23.07.2021 bei der Weltorganisation für geistiges Eigentum angemeldet.

Markendetails Letztes Update: 30. Juni 2023

Markenform Wortmarke
Aktenzeichen 1638231
Registernummer UK00003599711
Länder Europäische Gemeinschaft Japan Vereinigte Staaten von Amerika (USA)
Basismarke GB Nr. UK00003599711, 02. Juli 2021
Anmeldedatum 23. Juli 2021
Ablaufdatum 23. Juli 2031

Markeninhaber

Oxford Science Park, Medawar Centre,
2nd Floor East Building,
GB

Markenvertreter

14 South Square, Gray's Inn GB

Waren und Dienstleistungen

05 Pharmaceuticals; pharmaceutical preparations and substances; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein or nucleic acids or viral vectors for therapy; medicine; medical preparations and articles; biological preparations for medical purposes; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; biological preparations comprising exosome; biological preparations comprising a therapeutic target protein-loaded, nucleic acid-loaded or virus-loaded exosome; biological reagents for medical use; mixed biological preparations for medical purposes; mixed biological preparations for the prevention and treatment of infectious diseases; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, EV-based nucleic acid therapeutics for the prevention and treatment of infections or disease; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
42 Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific research and analysis services; biological research; clinical research; providing medical and scientific research information in the field of filtration of exosomes from cultured cells or blood; scientific investigations for medical purposes; scientific laboratory services; medical laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; laboratory diagnostics; information, advisory and consultancy services relating to the aforesaid
44 Medical services; medical and pharmaceutical consultancy; medical diagnostics; medical analysis and examinations; medical treatment services; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; information, advisory and consultancy services relating to the aforesaid
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen

Markenhistorie

Datum Belegnummer Bereich Eintrag
27. Juni 2023 2023/26 Gaz US RAW: Rule 18ter(2)(ii) GP following a provisional refusal
13. Oktober 2022 2022/41 Gaz JP Ablehnung
26. Mai 2022 2022/21 Gaz EM Ablehnung
21. April 2022 2022/16 Gaz US Ablehnung
23. Juli 2021 2021/51 Gaz GB Eintragung

ID: 141638231